Navigation Links
ESMO 2012 Congress: A path for medical oncology innovations
Date:6/13/2012

"The oncology field is going to explode within the next five years and in ten years from now oncology will be drastically different from what it is today: what we are going to see at ESMO 2012 in Vienna will give a broad overview of how new technologies can improve the tailoring of cancer therapies for the benefit of our patients." --Martine Piccart, ESMO and ESMO 2012 Congress President

More than 17,000 participants from over 120 different countries are coming to Vienna for the 37th congress of the European Society for Medical Oncology, including oncology professionals, healthcare policy makers, patient groups, pharmaceutical industry (85 exhibitors), cancer foundations and representatives of international media.

Over 200 program hours with 140 sessions, of which 110 presenting scientific results on cancer research progress in 2012, including late-breaking abstracts on gastrointestinal tumors, lung cancer, genitourinary tumors, breast cancer, gynecological cancers. Over 300 international experts will share best knowledge in cancer research, treatment and patient care.

Congress Program Highlights

  • More than 2,200 abstracts submitted, including 44 late-breaking abstracts, possibly foreshadowing important changes in clinical practice More details will be available at the end of July

  • Genomics opening new doors in the development of cancer treatments Read the interview with Dr Martine Piccart, ESMO President http://www.esmo.org/events/vienna-2012-congress/program/committe-member-erika-martinelli.html

  • Personalized medicine: the importance of patient selection in treatment efficacy from the early phases of drug development

  • Issues in the management of cancer in young women

  • Cancer prevention and screening: evidence-based answers to critical questions, including inherited cancers, and European screening guidelines

  • Public policy:
    • The need for harmonization of the approval process and reimbursement systems of new oncology drugs in Europe
    • Cost effectiveness and clinical trials: a new paradigm?
    • The role of cancer registries in support of planning and assessing population based oncology outcomes

  • First presentation of the findings of the International Collaborative Project on the availability and accessibility of opioids for the management of cancer pain

  • Four keynote lectures: for the first time oriented towards transversal topics, reaching beyond individual disease types, providing a topline picture of the evolution of cancer knowledge and cancer care

  • Controversy sessions: six lively and thought-provoking discussions on particularly hot topics based on latest research results

  • ESMO Clinical Practice Guidelines sessions: open discussions on individual cases to share the best of cancer care based on newly released and updated standards

  • ESMO Designated Centers of Integrated Oncology and Palliative Care announced as centers of excellence for patient care in Europe

  • ESMO Award, Hamilton Fairley Award, ESMO Lifetime Achievement Award and Georges Math Award recipients announced, to recognize prominent oncologists who have made outstanding contributions to the development of oncology and are internationally renowned for their achievements in cancer science and clinical / laboratory research

  • "2084": An inspirational and provocative play in three acts addressing the obstacles to conducting clinical research in the ever-evolving field of oncology
    "I think you're forgetting something, the authors of that trial never got prospective consent for this test to be used on archival patient's material."
    "How could they? The assay was only described two years ago!"
    "But that's not the point, you should know by now that all biological studies on any materials taken from patients in clinical trials for one purpose cannot be used for another purpose without the patient's fully informed consent."
    "But that's absurd, all those patients will have died decades ago. Am I to get consent posthumously?"

The ESMO 2012 Congress full program is available at http://www.esmo.org/events/vienna-2012-congress/program.html

Meeting venue and accommodation

The ESMO 2012 Congress will take place at the Austria Center Vienna, which is located 15 minutes from the city center, within walking distance from the underground station (U1 line) and just a 25 minutes' drive from the airport.

ACV - AUSTRIA CENTER VIENNA http://www.acv.at/
Bruno-Kreisky-Platz 1
1220 Vienna

As Vienna is a highly popular tourist destination, we advise you to book your hotel accommodation as soon as possible: http://www.esmo.org/events/vienna-2012-congress/accommodation.html

Media registration

ESMO welcomes media interested in obtaining information and reporting on cancer issues. Registration is free to bona fide journalists on presentation of a letter of assignment and a valid press card.

Media representatives are required to observe and abide by the ESMO 2012 Media Policy http://www.esmo.org/fileadmin/media/pdf/2012/events/vienna/ESMO-media-policy-update-2012-06.pdf .

To register for the event, please fill out the Complimentary Media Registration Form

Media registration in advance is strongly recommended (deadline: Monday, 24 September 2012).

A fully equipped ESMO Press Center will be available to registered journalists, including a press room with technical facilities (computers, wi-fi internet, telephones, photocopier, etc.), private interview rooms, storage cabinets for your technical equipment. On-site staff will be permanently at your disposal for any question and to facilitate one-on-one interviews with researchers and key opinion leaders, both in presence and remotely.

ESMO Press Program

The official ESMO 2012 Press Program will be developed in the following months, after review and acceptance of submitted abstracts. Details will be progressively uploaded on http://www.esmo.org/events/vienna-2012-congress/press.html.

In the meantime you can mark your diaries with important appointments for the press: ESMO 2012 Congress Preliminary Press Program Overview.


'/>"/>

Contact: Thomas Balasso
media@esmo.org
European Society for Medical Oncology
Source:Eurekalert

Related biology news :

1. Nanotechnology breakthrough could dramatically improve medical tests
2. MADRID-MIT M+Vision Consortium hosts Biomedical Innovation Conference 2012
3. Nuisance seaweed found to produce compounds with biomedical potential
4. CDS Monarch Deploys DigitalPersona Strong Authentication Solutions for Secure Access to Electronic Medical Records
5. Tufts Medical Center researchers finds marker in premies saliva predicts readiness to feed by mouth
6. UH Case Medical Center, CardioKinetix reveal promising data for treatment for heart failure
7. Ultrasensitive biosensor promising for medical diagnostics
8. Medical device, health professionals attend first national conference on value-driven engineering
9. Mainz University Medical Center attracts funding of Alexander von Humboldt Professorship
10. Research!America says house funding levels for FY13 could undermine medical progress
11. Miniature pressure sensors for medical touch
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/13/2016)... , January 13, 2016 ... the addition of the  "India Biometrics ... & Forecast (2015-2020)"  report to ... ) has announced the addition of ... Market - Estimation & Forecast (2015-2020)" ...
(Date:1/11/2016)... -- higi, the leading retail and omni-channel community engagement platform ... mobile, today announced it has closed funding of ... --> --> The ... health platform – its network of health stations, ... services and programs to retail partners and healthcare ...
(Date:1/8/2016)... 2016 NXTD ), a company ... , a privately held leading direct seller of vacation ... 5000 fastest-growing company announced that on December 31, 2015, ... in Nxt-ID to develop a proprietary new wireless smart ... , a unique smart wallet that serves to securely ...
Breaking Biology News(10 mins):
(Date:2/10/2016)... ... February 10, 2016 , ... HOLLOWAY AMERICA, a leading custom ... Rocky Mountain Chapter 21st Annual Vendor Exhibition on Thursday, February 18, 2016. The ... for its annual event, which will run from 3:00 p.m. - 8:30 p.m. ...
(Date:2/10/2016)... San Mateo, CA (PRWEB) , ... February 10, ... ... Registry of Multiplex Testing (PROMPT), a research registry built on the secure online ... in September 2014. More than 1,600 participants have joined the PROMPT study, which ...
(Date:2/10/2016)... ... , ... Cenna Bioscience Inc., an emerging biopharmaceutical company focused on the discovery ... has been selected to present at the Cavendish Global Health Impact Forum taking place ... purpose of the Forum is to help family offices and foundations develop and implement ...
(Date:2/9/2016)... , Feb. 9, 2016  Regenicin, Inc. ... company specializing in the development and commercialization of ... damaged tissues and organs, recently reported the Company,s ... first quarter of 2016. Lonza America ... new 2015 fiscal year in the process of ...
Breaking Biology Technology: